Positive News SentimentPositive NewsNYSE:BHVN Biohaven (BHVN) Stock Forecast, Price & News $17.53 +1.25 (+7.68%) (As of 05/31/2023 ET) Add Compare Share Share Today's Range$16.32▼$17.5750-Day Range$12.64▼$17.5352-Week Range$5.54▼$20.57Volume2.73 million shsAverage Volume773,467 shsMarket Capitalization$1.20 billionP/E RatioN/ADividend YieldN/APrice Target$38.39 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Biohaven MarketRank™ ForecastAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside119.0% Upside$38.39 Price TargetShort InterestBearish11.80% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.55Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.72) to ($4.50) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.19 out of 5 starsMedical Sector388th out of 1,006 stocksPharmaceutical Preparations Industry181st out of 492 stocks 3.4 Analyst's Opinion Consensus RatingBiohaven has received a consensus rating of Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $38.39, Biohaven has a forecasted upside of 119.0% from its current price of $17.53.Amount of Analyst CoverageBiohaven has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted11.80% of the float of Biohaven has been sold short.Short Interest Ratio / Days to CoverBiohaven has a short interest ratio ("days to cover") of 7.6.Change versus previous monthShort interest in Biohaven has recently decreased by 2.00%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldBiohaven does not currently pay a dividend.Dividend GrowthBiohaven does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BHVN. Previous Next 3.6 News and Social Media Coverage News SentimentBiohaven has a news sentiment score of 1.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Biohaven this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for BHVN on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat Follows4 people have added Biohaven to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Biohaven insiders have not sold or bought any company stock.Percentage Held by Insiders12.40% of the stock of Biohaven is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions98.01% of the stock of Biohaven is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Biohaven are expected to grow in the coming year, from ($4.72) to ($4.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biohaven is -1.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biohaven is -1.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiohaven has a P/B Ratio of 2.53. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Biohaven (NYSE:BHVN) StockBiohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. The company's pipeline products include BHV-7000, a potassium channel activator for the treatment of focal epilepsy; Troriluzole, a tripeptide prodrug that is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500, a low-trapping glutamate N-methyl-D-aspartate receptor antagonist for neuropathic pain; and Verdiperstat, an irreversible myeloperoxidase enzyme inhibitor for the treatment of neurodegenerative diseases. It also offers Taldefgrobep Alfa, an anti-myostatin adnectin, which is in Phase 3 clinical trial to treat spinal muscle atrophy; and BHV-1100 that is in Phase 1a/1b clinical trial for multiple myeloma patients. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in Sept 2022. The company was incorporated in 2022 and is headquartered in New Haven, Connecticut. Biohaven Ltd. is a subsidiary of Biohaven Pharmaceutical Holding Company Ltd.Read More Receive BHVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biohaven and its competitors with MarketBeat's FREE daily newsletter. Email Address BHVN Stock News HeadlinesMay 31, 2023 | finance.yahoo.comBiohaven Provides Overview of Clinical Progress, Regulatory Updates, and Pipeline Developments at R&D DayMay 25, 2023 | finance.yahoo.comBiohaven to Present R&D Day at Yale School of ManagementJune 1, 2023 | Edge On The Street (Ad)Graphite versus Lithium - What Investors Should KnowOver 18 million EVs will be cruising U.S roads by 2030. And every one million EVs manufactured will require 82,000 tons of the metal graphite for their batteries. That's a total of 1,476,000 tons of graphite! Graphite is actually the largest component of EV batteries - NOT lithium. Experts warn of a massive graphite shortfall, especially since North America currently has no operating graphite mines.May 24, 2023 | americanbankingnews.comBiohaven (NYSE:BHVN) Trading Up 5.1%May 21, 2023 | americanbankingnews.comFY2023 Earnings Estimate for Biohaven Ltd. Issued By Cantor Fitzgerald (NYSE:BHVN)May 20, 2023 | americanbankingnews.comBrokerages Set Biohaven Ltd. (NYSE:BHVN) PT at $38.39May 18, 2023 | markets.businessinsider.comSVB Securities Reaffirms Their Buy Rating on Biohaven Ltd. (BHVN)May 15, 2023 | benzinga.comBiohaven shares are trading higher after the company reported better-than-expected Q1 EPS results.June 1, 2023 | Edge On The Street (Ad)Graphite versus Lithium - What Investors Should KnowOver 18 million EVs will be cruising U.S roads by 2030. And every one million EVs manufactured will require 82,000 tons of the metal graphite for their batteries. That's a total of 1,476,000 tons of graphite! Graphite is actually the largest component of EV batteries - NOT lithium. Experts warn of a massive graphite shortfall, especially since North America currently has no operating graphite mines.May 12, 2023 | msn.comRecap: Biohaven Q1 EarningsMay 12, 2023 | finance.yahoo.comBiohaven Reports First Quarter 2023 Financial Results and Reports Recent Business DevelopmentsMay 5, 2023 | finance.yahoo.comIs Biohaven (NYSE:BHVN) In A Good Position To Deliver On Growth Plans?May 4, 2023 | americanbankingnews.comShort Interest in Biohaven Ltd. (NYSE:BHVN) Decreases By 5.5%April 25, 2023 | americanbankingnews.comBiohaven Ltd. (NYSE:BHVN) Receives $38.39 Consensus Target Price from BrokeragesApril 19, 2023 | americanbankingnews.comBiohaven (NYSE:BHVN) Shares Up 7.8%April 17, 2023 | finance.yahoo.comBiohaven Expands Executive Leadership Team with Appointment of Nick Kozauer M.D. as Senior Vice President for Clinical Development and Regulatory StrategyApril 4, 2023 | americanbankingnews.comCantor Fitzgerald Increases Biohaven (NYSE:BHVN) Price Target to $31.00March 31, 2023 | americanbankingnews.comAnalysts Set Biohaven Ltd. (NYSE:BHVN) Target Price at $48.75March 30, 2023 | finance.yahoo.comIs Biohaven Ltd. (BHVN) Stock Outpacing Its Medical Peers This Year?March 25, 2023 | finance.yahoo.comBullish Biohaven Ltd. (NYSE:BHVN) insiders filled their treasuries with US$37m worth of stock over last yearMarch 23, 2023 | finance.yahoo.comBiohaven Reports Fourth Quarter and Full Year 2022 Financial Results and Reports Recent Business DevelopmentsMarch 22, 2023 | finance.yahoo.comBiohaven Acquires Exclusive License for Oral, Brain-Penetrant, Dual TYK2/JAK1 Inhibitor for Immune-Mediated Brain DisordersFebruary 21, 2023 | finance.yahoo.comBiohaven's Taldefgrobep Alfa Receives FDA Fast Track Designation for Spinal Muscular AtrophyFebruary 2, 2023 | finance.yahoo.comHere's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad CoricJanuary 5, 2023 | finance.yahoo.comIs Biohaven Ltd. (BHVN) Outperforming Other Medical Stocks This Year?December 23, 2022 | finance.yahoo.comBiohaven Ltd.'s (NYSE:BHVN) market cap dropped US$151m last week; individual investors who hold 55% were hit as were institutionsNovember 29, 2022 | finance.yahoo.comAfter Plunging 13% in 4 Weeks, Here's Why the Trend Might Reverse for Biohaven Ltd. (BHVN)See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive BHVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biohaven and its competitors with MarketBeat's FREE daily newsletter. Email Address BHVN Company Calendar Last Earnings3/23/2023Today6/01/2023Next Earnings (Estimated)8/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:BHVN Previous SymbolNASDAQ:BHVN CUSIPN/A CIK1689813 Webwww.biohavenpharma.com Phone203-404-0410FaxN/AEmployees928Year FoundedN/APrice Target and Rating Average Stock Price Forecast$38.39 High Stock Price Forecast$148.50 Low Stock Price Forecast$21.00 Forecasted Upside/Downside+119.0%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($12.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-570,280,000.00 Net MarginsN/A Pretax Margin-255.54% Return on Equity-1,023.06% Return on Assets-111.60% Debt Debt-to-Equity RatioN/A Current Ratio4.78 Quick Ratio4.78 Sales & Book Value Annual Sales$462.51 million Price / Sales2.59 Cash FlowN/A Price / Cash FlowN/A Book Value$6.92 per share Price / Book2.53Miscellaneous Outstanding Shares68,220,000Free Float57,650,000Market Cap$1.20 billion OptionableOptionable Beta1.04 Key ExecutivesDr. Vladimir Coric M.D. (Age 51)Chairman & CEO Mr. Matthew Buten (Age 61)Chief Financial Officer Mr. George C. Clark (Age 38)VP & Chief Accounting Officer Dr. Bruce D. Car DACVP (Age 61)Ph.D., Chief Scientific Officer Ms. Jennifer PorcelliVP of Investor RelationsMr. Warren VollesGen. Counsel & Chief Legal OfficerMr. Clifford Bechtold M.S.Chief Compliance OfficerMs. Kimberly Gentile (Age 56)Sr. VP of Clinical Operations Mr. John Tilton (Age 54)Chief Commercial Officer of Rare Diseases Mr. Chris BarrettSr. VP of Commercial Strategy, Common DiseaseMore ExecutivesKey CompetitorsSummit TherapeuticsNASDAQ:SMMTOPKO HealthNASDAQ:OPKDeciphera PharmaceuticalsNASDAQ:DCPHStructure TherapeuticsNASDAQ:GPCRArvinasNASDAQ:ARVNView All CompetitorsInsiders & InstitutionsPutnam Investments LLCBought 1,508 shares on 5/22/2023Ownership: 0.037%JPMorgan Chase & Co.Sold 377,424 shares on 5/18/2023Ownership: 0.451%New York State Common Retirement FundSold 13,539 shares on 5/18/2023Ownership: 0.048%Fred Alger Management LLCSold 33,441 shares on 5/16/2023Ownership: 0.246%Susquehanna International Group LLPSold 27,600 shares on 5/16/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions BHVN Stock - Frequently Asked Questions Should I buy or sell Biohaven stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biohaven in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BHVN shares. View BHVN analyst ratings or view top-rated stocks. What is Biohaven's stock price forecast for 2023? 7 analysts have issued 1-year price objectives for Biohaven's stock. Their BHVN share price forecasts range from $21.00 to $148.50. On average, they anticipate the company's share price to reach $38.39 in the next twelve months. This suggests a possible upside of 119.0% from the stock's current price. View analysts price targets for BHVN or view top-rated stocks among Wall Street analysts. How have BHVN shares performed in 2023? Biohaven's stock was trading at $13.88 at the beginning of the year. Since then, BHVN stock has increased by 26.3% and is now trading at $17.53. View the best growth stocks for 2023 here. Are investors shorting Biohaven? Biohaven saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 7,010,000 shares, an increase of 5.1% from the April 15th total of 6,670,000 shares. Based on an average daily volume of 883,100 shares, the short-interest ratio is currently 7.9 days. Currently, 12.1% of the company's stock are short sold. View Biohaven's Short Interest. When is Biohaven's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 4th 2023. View our BHVN earnings forecast. How were Biohaven's earnings last quarter? Biohaven Ltd. (NYSE:BHVN) posted its quarterly earnings results on Thursday, March, 23rd. The company reported ($3.32) earnings per share for the quarter, missing the consensus estimate of ($1.24) by $2.08. What ETFs hold Biohaven's stock? ETFs with the largest weight of Biohaven (NYSE:BHVN) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Vanguard Russell 2000 Growth ETF (VTWG), Vanguard Russell 2000 Value ETF (VTWV), Inspire Global Hope ETF (BLES) and Principal Healthcare Innovators ETF (BTEC). What other stocks do shareholders of Biohaven own? Based on aggregate information from My MarketBeat watchlists, some companies that other Biohaven investors own include AbbVie (ABBV), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Alibaba Group (BABA), ACADIA Pharmaceuticals (ACAD), QUALCOMM (QCOM), Pfizer (PFE), Sarepta Therapeutics (SRPT) and Abbott Laboratories (ABT). When did Biohaven IPO? (BHVN) raised $124 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 8,300,000 shares at $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital served as the underwriters for the IPO and William Blair and Needham & Company were co-managers. What is Biohaven's stock symbol? Biohaven trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHVN." Who are Biohaven's major shareholders? Biohaven's stock is owned by a number of institutional and retail investors. Top institutional investors include State Street Corp (6.67%), BlackRock Inc. (6.32%), FMR LLC (5.36%), Armistice Capital LLC (4.58%), Price T Rowe Associates Inc. MD (2.41%) and Pictet Asset Management SA (1.77%). Insiders that own company stock include Declan Doogan, Elyse Stock, George C Clark, Gregory Bailey, James Engelhart, John Tilton, John W Childs, Julia P Gregory, Kimberly Gentile, Matthew Buten, Robert Berman, Vlad Coric and William A Jones Jr. View institutional ownership trends. How do I buy shares of Biohaven? Shares of BHVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Biohaven's stock price today? One share of BHVN stock can currently be purchased for approximately $17.53. How much money does Biohaven make? Biohaven (NYSE:BHVN) has a market capitalization of $1.20 billion and generates $462.51 million in revenue each year. The company earns $-570,280,000.00 in net income (profit) each year or ($12.31) on an earnings per share basis. How many employees does Biohaven have? The company employs 928 workers across the globe. How can I contact Biohaven? Biohaven's mailing address is 215 CHURCH STREET, NEW HAVEN CT, 06510. The official website for the company is www.biohavenpharma.com. The company can be reached via phone at 203-404-0410 or via email at jennifer.porcelli@biohavenpharma.com. This page (NYSE:BHVN) was last updated on 6/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biohaven Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.